Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Zivo Bioscience, Inc.

Get SEC filing alerts via email and in your feed for Zivo Bioscience, Inc.

ZIVO ZIVOW

Zivo Bioscience, Inc.

About Zivo Bioscience, Inc.

Zivo Bioscience Inc. is a biotech and agtech research company specializing in proprietary algal and bacterial strains, bioactive molecules, and cultivation techniques. Its core focus is developing immune-modulating and nutritional products for human and animal health, including treatments for poultry diseases, livestock, pets, and human immune support. The company leverages patented technologies, strategic partnerships, and regulatory approvals to commercialize sustainable, non-antibiotic solutions in global health and nutrition markets.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Zivo Bioscience, Inc.

1
1
Zivo Bioscience, Inc. Zivo Bioscience Reports Revenue Growth but Faces Significant Losses and Liquidity Challenges

Via official filing (AI summary) | 7 months ago | 0 comments

2
1
Zivo Bioscience, Inc. Zivo Bioscience Reports Revenue Growth to $53,400 but Faces $1.6M Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

3
1
Zivo Bioscience, Inc. Zivo Bioscience Reports No Revenue and Increased Losses in Latest Financial Filing

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Zivo Bioscience, Inc. Zivo Bioscience Reports 468% Revenue Increase to $157,220, Faces $13.4 Million Net Loss

Via official filing (AI summary) | over 1 year ago | 0 comments

5
1
Zivo Bioscience, Inc. Zivo Bioscience Reports Significant Revenue Growth, Wider Losses in Q3 and Nine Months 2024

Via official filing (AI summary) | over 1 year ago | 0 comments